查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
CAR-T細胞療法的全球市場 - 市場規模，預測，實驗，趨勢(2025年)
市場調查報告書
商品編碼
1609195

CAR-T細胞療法的全球市場 - 市場規模，預測，實驗，趨勢(2025年)

Global CAR-T Cell Therapy Market - Market Size, Forecasts, Trials & Trends, 2025
出版日期: | 出版商: BioInformant | 英文 332 Pages | 訂單完成後即時交付

價格
簡介目錄

摘要整理

CAR-T細胞療法對於癌症患者來說是一種極具前景的治療方法。這是一種免疫療法，醫生收集免疫細胞，在實驗室修改它們，並賦予它們識別和殺死癌細胞的能力。一旦注射到患者體內，細胞就會繁殖並作為 "活藥" 保留在體內。

CAR-T療法的支柱是T細胞。 T 細胞對於免疫系統引導免疫反應和消除被病原體感染的細胞的能力至關重要。 CAR-T 療法包括從患者身上抽取血液並分離 T 細胞。這些細胞在實驗室中使用改良病毒進行基因工程改造，在 T 細胞表面產生嵌合抗原受體 (CAR)。一旦被重新引入患者體內，這種 CAR 就可以讓 T 細胞識別並結合癌細胞上的特定抗原，從而消滅它們。

2017年至今，已有11個CAR-T產品商業化。其中七種是美國 FDA 批准的 CAR T 細胞療法，每種療法也獲得了其他主要醫療市場的批准。

美國FDA認證的7個產品如下列。

  • Kymriah - Novartis賓夕法尼亞大學和共同開發。Novartis銷售。
  • Yescarta - Gilead Sciences的子公司Kite Pharma開發。Gilead Sciences銷售。
  • Tecartus - Gilead Sciences的子公司Kite Pharma開發。Gilead Sciences銷售。
  • Breyanzi - Bristol-Myers Squibb(BMS)所收購的Juno Therapeutics(Celgene的子公司)開發。BMS銷售。
  • Abecma - bluebird bioBristol-Myers Squibb(BMS)和共同開發。BMSbluebird 與bio共同銷售。
  • Carvykti - Legend Biotech作為Johnson & Johnson的子公司的Janssen Biotech和共同開發。Janssen Biotech和Legend Biotech銷售。
  • Aucatzyl - Autolus Therapeutics開發。

此外，Relma-cel和元瑞達兩種CAR-T療法已獲得中國NMPA批准。此外，印度 CDSCO 也批准了兩種 CAR-T 療法：NexCAR19 和 Qartemi。

這些批准顯示了 CAR-T 市場的快速成長，並對生物技術產業產生了重大影響。併購尤其活躍，新基 (Celgene) 在 2018 年以 90 億美元收購了 Juno Therapeutics，百時美施貴寶 (BMS) 在 2019 年以 740 億美元收購了新基 (Celgene)。吉利德以 119 億美元收購 Kite Pharma 也成為頭條新聞。

價值 10 億美元的 CAR T 細胞治療市場的成功很大程度上歸功於早期治療在治療血癌方面的顯著效果。然而，CAR-T療法的下一個重大課題是擴大其在實體腫瘤治療的應用。目前，市面上所有九種 CAR-T 產品以及近 75% 正在進行的臨床試驗都採用自體方法（使用患者自己的細胞）。使用供體細胞開發同種異體 CAR-T 療法預計將創造巨大的市場機會。

CAR-T 療法的另一個障礙是從血漿分離術（收穫 T 細胞的過程）到交付最終產品的 "靜脈到靜脈" 時間。由於這個過程可能會延長，通常建議用盡其他治療選擇的末期病人使用 CAR-T 療法。此外，報銷仍然是美國和歐洲的一個主要課題。

本報告調查了全球 CAR-T 細胞治療市場，並對 CAR-T 細胞治療現狀和 CAR-T 行業狀況進行了詳細分析。我們還涵蓋已批准的 CAR-T 療法和可能很快商業化的後期臨床試驗。

目錄

第1章 報告概要

第2章 CAR-T細胞療法:技術開發

  • CAR-T細胞療法概述
  • CAR-T 開發的演變
  • 造血惡性細胞中存在的抗原
  • 將受體基因插入 T 細胞的工具
  • T 細胞轉化為 CAR-T 細胞
  • 11 種市售 CAR-T 療法：概述
    • Kymriah (tisagenlecleucel)
    • Yescarta (axicabtagene ciloleucel)
    • Tecartus (brexucabtagene autoleucel)
    • Carvykti (ciltacabtagene autoleucel)
    • Abecma (idecabtagene vicleucel)
    • Breyanzi (lisocabtagene maraleucel)
    • Relma-cel (relmacabtagene autoleucel)
    • NexCAR19 (Actalycabtagene autoleucel)
    • Yuanruida (inaticabtagene autoleucel，CNCT19)
    • Qartemi (varnimcabtagene autoleucel)
    • Aucatzyl (obecabtagene autoleucel)
  • CAR-T治療伴隨的毒性

第3章 未來的CAR-T療法的策略

  • 可切換 CAR (sCAR)
  • 破壞體內CAR-T細胞的自殺基因
  • 瞬時轉染
  • 親和力調整的 CAR
  • 裝甲車
  • 從血癌到實體癌症的轉變
  • 注重縮短住院時間
  • 專注於發現新抗原
  • 從自體 CAR-T 療法過渡到同種異體 CAR-T 療法
  • 面向大眾的 CAR-T
  • 一種新的體內 CAR-T 方法
  • 與 mRNA 疫苗組合
  • 與溶瘤病毒組合

第4章 CAR-T開發主要的事件(1989年～2024年)

  • CAR-T 開發時間表
  • CAR-T 療法實現的 10 個里程碑
  • CAR-T療法產品的現狀
  • 未來 CAR-T 之星
  • CAR-T療法針對的癌症患者
  • CAR-T細胞療法的優勢
  • CAR-T細胞療法的缺點

第5章 CAR-T細胞的可伸縮的製造

  • 臨床規模的自體 CAR-T 療法製造工藝
  • CAR-T細胞製造平台的演變

第6章 CAR-T標的抗原

  • 血癌中的CAR-T標靶抗原
  • 實體腫瘤上的 CAR-T 標靶抗原
  • 臨床試驗中 CAR-T 細胞標靶的常見抗原

第7章 CAR-T的專利形勢

  • CAR-T專利的地理分佈
  • CAR-T專利申請量排名前10名的公司
  • 擁有 CAR-T 專利發明的前 10 家公司
  • 擁有 CAR-T 專利的前 10 家公司
  • CAR-T專利的法律地位

第8章 CAR-T的臨床試驗形勢

  • 臨床試驗中最常見的適應症
  • 正在進行的臨床試驗的重點
  • 臨床試驗：依國家分類
  • 研究階段
  • CAR-T 臨床試驗：依經費類型劃分
  • 臨床試驗中治療的造血系統惡性腫瘤類型
  • 使用一個 CAR-T 同時定位
  • 臨床試驗中使用的 CAR-T 世代類型
  • 針對實體腫瘤的CAR-T臨床試驗
  • CAR-T 研究的分佈：以使用的 SeFv 類型分類
  • CAR-T 測試的分佈：依所使用的載具類型
  • 實體腫瘤CAR-T研究的地理分佈
  • 臨床試驗中的 CAR-T 標靶生物標記
  • 臨床試驗中CAR-T結構的完善

第9章 PUBMED.GOV所發表的CAR-T科學論文

  • 來自 PubMed.gov 的自體和同種異體 CAR-T 療法的文章
  • PubMed.gov 上有關 CAR-T 治療血癌和實體瘤的文章（2013 年至 2024 年 3 月）
  • 關於第五代 CAR 的 PubMed 文章
  • NIH 為 CAR-T 研究提供資金

第10章 CAR-T的資金籌措形勢

  • CAR-T 領域的創投（2014 年至 2024 年 3 月）
  • 投資 CAR-T 公司的 IPO 融資（2014 年-2024 年 3 月）
  • CAR-T 許可協議
  • CAR-T 合作協議
  • CAR-T 併購 (M&A) 交易（2015 年至 2024 年 3 月）
  • CAR-T 資金概覽

第11章 與CAR-T治療的成本償付

  • 新的支付模式
  • 美國 CAR-T 療法的報銷
  • 歐洲 CAR-T 療法的費用
  • 亞洲 CAR-T 療法的費用和報銷

第12章 CAR-T治療的血液癌症

  • 急性淋巴性白血病（ALL）
  • 瀰漫性大 B 細胞淋巴瘤 (DLBCL)
  • 套細胞淋巴瘤 (MCL)
  • 多發性骨髓瘤 (MM)
  • 濾泡性淋巴瘤
  • 血癌治療的龐大費用

第13章 市場分析

  • CAR-T細胞療法的普及性（2017-2023）
    • 目前 CAR-T 細胞療法的全球市場：依產品分類
  • CAR-T細胞治療產品全球市場預測（2024-2032年）
    • CAR-T 療法的全球市場：按地區劃分
    • CAR-T 療法的全球市場：依適應症分類
  • CAR-T 療法治療血癌的課題與機會
    • 訪問障礙
    • CD19 以外的目標
    • 對 CAR-T 療法的抗藥性
    • 生產時間
    • 自體 CAR-T 與同種異體 CAR-T

第14章 CAR-T企業:概要

  • 2seventy bio
  • Abintus Bio, Inc.
  • AffyImmune Therapeutics, Inc.
  • Aleta BioTherapeutics
  • Allogene Therapeutics
  • Anixa Biosciences, Inc.
  • Arbele, Ltd.
  • Arcellx
  • Atara Biotherapeutics
  • Aurora BioPharma
  • Autolus Therapeutics plc
  • AvenCell Europe GmbH
  • Beam Therapeutics, Inc.
  • Bellicum Pharmaceuticals
  • BioNTech
  • Biosceptre
  • Bluebird bio
  • Bristol Myers Squibb/Celgene Corporation
  • Cabaletta Bio
  • Carina Biotech
  • CARsgen Therapeutics
  • Cartesian Therapeutics
  • CARTherics Pty Ltd.
  • CASI Pharmaceuticals
  • Cellectis
  • Celularity, Inc.
  • Celyad Oncology
  • CRISPR Therapeutics
  • Curocell, Inc.
  • DiaCarta
  • Elicera Therapeutics AB
  • EXUMA Biotech
  • Fate Therapeutics
  • Galapagos NV
  • Gilead Sciences, Inc.
  • Gracell Biotechnologies
  • IASO Biotherapeutics
  • ImmPACT Bio
  • Immuneel Therapeutics, Pvt., Ltd.
  • ImmunoACT
  • Interius BioTherapeutics
  • Juventas Cell Therapy
  • JW Therapeutics
  • Kite Pharma (Gilead)
  • Kyverna Therapeutics
  • Legend Biotech
  • Leucid Bio
  • Luminary Therapeutics, Inc.
  • Lyell Immunopharma, Inc.
  • March Biosciences
  • MaxCyte, Inc.
  • Minerva Biotechnologies Corporation
  • Mustang Bio
  • Noile-Immune Biotech
  • Novartis AG
  • Oncternal Therapeutics
  • Oxford Biomedica plc
  • PeproMene Bio, Inc.
  • Poseida Therapeutics, Inc.
  • Precigen, Inc.
  • Prescient Therapeutics
  • ProMab Biotechnologies, Inc.
  • SOTIO Biotech BV
  • Syngene International, Ltd.
  • Synthekine
  • TC BioPharm
  • T-CURX
  • Umoja Biopharma
  • ViTToria Biotherapeutics
  • Vor Biopharma
  • Wugen
  • WuXi Advanced Therapies
  • Xenetic Biosciences
  • Xyphos Biosciences, Inc.

圖的索引

表的索引

簡介目錄

EXECUTIVE SUMMARY

CAR-T cell therapy is a remarkably promising treatment for cancer patients. It is a type of immunotherapy where doctors collect immune cells, modify them in a laboratory, and provide them the power to identify and kill cancer cells. When infused into a patient, the cells get multiplied and stay in the body as "living drugs."

The backbone of CAR-T therapy is T-cells, which are essential to the immune system's ability to direct immune responses and eliminate cells infected by pathogens. For CAR-T therapy, blood is drawn from the patient, and T-cells are isolated. These cells are then genetically engineered in the laboratory using a modified virus, which enables the T-cells to produce chimeric antigen receptors (CARs) on their surface. Once reintroduced into the patient's body, these CARs allow the T-cells to recognize and bind to specific antigens on cancer cells, leading to their destruction.

From 2017 to today, 11 CAR-T products have reached commercialization. Of these, seven are U.S. FDA-approved CAR-T cell therapies, each of which have received approvals in other major healthcare markets as well.

The seven U.S. FDA approved products include:

  • Kymriah - Developed by Novartis in collaboration with the University of Pennsylvania. Marketed by Novartis.
  • Yescarta - Developed by Kite Pharma, a subsidiary of Gilead Sciences. Marketed by Gilead Sciences.
  • Tecartus - Developed by Kite Pharma, a subsidiary of Gilead Sciences. Marketed by Gilead Sciences.
  • Breyanzi - Developed by Juno Therapeutics (a Celgene company), which was acquired by Bristol-Myers Squibb (BMS). Marketed by BMS.
  • Abecma - Developed by bluebird bio in partnership with Bristol-Myers Squibb (BMS). Marketed by BMS in collaboration with bluebird bio.
  • Carvykti - Developed by Legend Biotech in partnership with Janssen Biotech, a subsidiary of Johnson & Johnson. Marketed by Janssen Biotech and Legend Biotech.
  • Aucatzyl - Developed and marketed by Autolus Therapeutics.

Additionally, two CAR-T therapies have been approved by the Chinese National Medical Products Administration (NMPA): Relma-cel and Yuanruida. Two CAR-T therapies have also been approved by the Indian Central Drugs Standard Control Organisation (CDSCO): NexCAR19 and Qartemi.

These approvals highlight the rapid growth of the CAR-T market, which is having a significant impact on the biotech industry. Mergers and acquisitions have been particularly active, with Celgene acquiring Juno Therapeutics for $9 billion in 2018, and Bristol-Myers Squibb (BMS) purchasing Celgene for $74 billion by 2019. Gilead's $11.9 billion acquisition of Kite Pharma also made headlines.

The billion-dollar CAR-T cell therapy market owes much of its success to the early therapies' impressive effectiveness in treating blood cancers. However, the next major challenge for CAR-T therapies will be expanding their use to treat solid tumors. Currently, all nine marketed CAR-T products, along with nearly 75% of ongoing clinical trials, utilize an autologous approach (using the patient's own cells). Developing allogeneic CAR-T therapies-using donor cells-will open up critical market opportunities.

Another hurdle for CAR-T therapies is the "vein-to-vein" time-the time between apheresis (the process of collecting the T-cells) and the delivery of the final product. This process can be lengthy, so CAR-T therapies are typically recommended for end-stage patients who have exhausted other treatment options. Additionally, reimbursement remains a significant challenge in the U.S. and Europe.

The industry is working to overcome these challenges. Several CAR-T companies are using advanced gene-transfer techniques to introduce CARs into T-cells more efficiently. Partnerships are also emerging to develop CRISPR and electroporation technologies to enhance T-cell modification. Additionally, some companies are incorporating "on-off" switches in CAR-T cells to prevent toxicity. Despite progress, achieving success with solid tumors has proven difficult, with clinical trials so far showing low response rates. The focus now is on identifying effective antigens specific to solid tumors.

This report provides detailed analysis of the current state of CAR-T cell therapies and the broader CAR-T industry landscape. It highlights approved CAR-T therapies and late-stage clinical trials that could reach commercialization soon. CAR-T companies, ranging from small startups to billion-dollar giants, are now proliferating in all major healthcare markets worldwide.

Key questions answered in this report include:

  • What are the most targeted antigens for liquid and solid tumors?
  • What developments are anticipated in the CAR-T sector, and what commercial opportunities and patient outcomes will they create?
  • How many CAR-T-related patent publications and granted patents have been issued since 2012?
  • Which countries hold the largest number of CAR-T patents?
  • Which companies have filed the most CAR-T patents?
  • Who are the leading inventors in CAR-T patent filings?
  • How many CAR-T clinical trials have been registered over the past 20 years?
  • Which biomarker antigens are most prominent in the CAR-T clinical trial landscape?
  • What are the most common indications being addressed by CAR-T clinical trials in the U.S. and China?
  • Which companies are leading CAR-T clinical trials?
  • How many deals have been made within the CAR-T sector in recent years?
  • Which promising CAR-T candidates are likely to reach commercialization soon?
  • How are CAR-T therapies reimbursed in the U.S. and Europe?
  • How many automated manufacturing systems are currently available in the global market?
  • What is the current market size for CAR-T cell therapies by geography, product, and indication?
  • What are the future market forecasts for CAR-T cell therapies by geography, product, and indication?
  • What barriers, risks, and opportunities exist for growth in the global CAR-T industry?
  • Who are the major companies developing CAR-T cell therapies, what are their core technologies, and what products do they have in development?

This global strategic report reveals:

  • Global CAR-T Cell Therapy Market Size, segmented by Product, Geography, and Indication, with future market size forecasts through 2032
  • In-depth coverage of approved CAR-T products, including regulatory approvals, pricing, reimbursement, and market penetration
  • Analysis of clinical trial activity by type, geography, phase, and sponsor
  • Comprehensive CAR-T patent analysis, including top inventors, patent holders, patent types, geographies, and the most cited patents
  • Overview of CAR-T industry mergers and acquisitions, IPOs, and financing events
  • Examination of strategic partnerships, alliances, and co-commercialization agreements within the CAR-T sector
  • Market trends, future directions, and emerging opportunities
  • Profiles of leading CAR-T competitors in the global marketplace
  • And so much more

TABLE OF CONTENTS

1. REPORT OVERVIEW

  • 1.2. Statement of the Report
  • 1.2. Executive Summary
  • 1.3. Introduction

2. CAR-T CELL THERAPY: TECHNOLOGY DEVELOPMENT

  • 2.1. CAR-T Cell Therapy Overview
  • 2.2. Evolution of CAR-T Development
    • 2.2.1. The CAR-T Cell Therapy Technology Progression
      • 2.2.1.1. First Generation CARs
      • 2.2.1.2. The Second Generation CARs
      • 2.2.1.3. Third Generation CARs
      • 2.2.1.4. Fourth Generation CARs
      • 2.2.1.5. Fifth Generation CARs
      • 2.2.1.6. CAR Constructs in the FDA Approved CAR-T Cell Products
  • 2.3. Antigens Present on Hematological Malignant Cells
  • 2.4. Tools for Inserting Receptor Genes into T Cells
  • 2.5. Transforming T Cells into CAR-T Cells
  • 2.6. The 11 CAR-T Therapies Available in the Market: A Brief Overview
    • 2.6.1. Kymriah (tisagenlecleucel)
      • 2.6.1.1. Indication
      • 2.6.1.2. Product Description & Mechanism of Action
      • 2.6.1.3. Manufacturing
      • 2.6.1.4. Dosage Composition
      • 2.6.1.5. Approval History
      • 2.6.1.6. Market
      • 2.6.1.7. Competition
    • 2.6.2. Yescarta (axicabtagene ciloleucel)
      • 2.6.2.1. Indication
      • 2.6.2.2. Product Description & Mechanism of Action
      • 2.6.2.3. Manufacturing Process of Yescarta
      • 2.6.2.4. Dosage Composition
      • 2.6.2.5. Approval History
      • 2.6.2.7. Sales Revenues
      • 2.6.2.8. Competitors
    • 2.6.3. Tecartus (brexucabtagene autoleucel)
      • 2.6.3.1. Indication
      • 2.6.3.2. Product Description & Mechanism of Action
      • 2.6.3.3. Tecartus Manufacturing Process
      • 2.6.3.4. Dosage Composition
      • 2.6.3.5. Approval History
      • 2.6.3.6. Sales Revenues
      • 2.6.3.7. Competitors
    • 2.6.4. Carvykti (ciltacabtagene autoleucel)
      • 2.6.4.1. Indication
      • 2.6.4.2. Product Description & Mechanism of Action
      • 2.6.4.3. Manufacturing Process of Carvykti
      • 2.6.4.4. Dosage & Composition
      • 2.6.4.5. Approval History
      • 2.6.4.6. Sales Revenues
      • 2.6.4.7. Competition
    • 2.6.5. Abecma (idecabtagene vicleucel)
      • 2.6.5.1. Indication
      • 2.6.5.2. Product Description and Mechanism of Action
      • 2.6.5.3. Manufacturing of Abecma
      • 2.6.5.4. Dosage & Composition
      • 2.6.5.5. Approval History
      • 2.6.5.6. Sales Revenues
      • 2.6.5.7. Competitors
    • 2.6.6. Breyanzi (lisocabtagene maraleucel)
      • 2.6.6.1. Indication
      • 2.6.6.2. Product Description & Mechanism of Action
      • 2.6.6.3. Manufacturing
      • 2.6.6.4. Breyanzi Dosage & Composition
      • 2.6.6.5. Approval History
      • 2.6.6.6. Sales Revenues
    • 2.6.7. Relma-cel (relmacabtagene autoleucel)
    • 2.6.8. NexCAR19 (Actalycabtagene autoleucel)
    • 2.6.9. Yuanruida (inaticabtagene autoleucel; CNCT19)
    • 2.6.10. Qartemi (varnimcabtagene autoleucel)
      • 2.6.10.1. Indication & Dosage
      • 2.6.10.2. Product Description & Mechanism of Action
      • 2.6.10.3. Manufacturing
    • 2.6.11. Aucatzyl (obecabtagene autoleucel)
      • 2.6.11.1. Product Description
      • 2.6.11.2. Indication & Dosage
      • 2.6.11.3. Mechanism of Action
      • 2.6.11.4. Manufacturing
      • 2.6.11.5. Competitor
  • 2.7. Toxicities Associated with CAR-T Treatment

3. STRATEGIES FOR FUTURE CAR-T THERAPIES

  • 3.1. Switchable CARs (sCARs)
  • 3.2. Suicide Genes to Destroy CAR-T Cells in vivo
  • 3.3. Transient Transfection
  • 3.4. Affinity-Tuned CARs
  • 3.5. Armored CARs
  • 3.6. Shifts from Liquid Cancers to Solid Tumors
  • 3.7. Focus on Shortening Hospital Stay
  • 3.8. Focus on Discovering New Antigens
  • 3.9. Shifting from Autologous to Allogeneic CAR-T Therapies
  • 3.10. CAR-T for the Masses
  • 3.11. New In Vivo CAR-T Approaches
  • 3.12. Combination with mRNA Vaccine
  • 3.13. Combination with Oncolytic Virus

4. MAJOR EVENTS DURING THE DEVELOPMENT OF CAR-T, 1989-2024

  • 4.1. CAR-T Development Timeline
  • 4.2. Top Ten Milestones Crossed by CAR-T Therapy
    • 4.2.1. First Pediatric Patient to Receive CAR-T Therapy
    • 4.2.2. CAR-T Granted Breakthrough Therapy Designation
    • 4.2.3. The Beginning of CAR-T Development to Combat Solid Cancers
    • 4.2.4. First CRISPR CAR-T Built
    • 4.2.5. The First Two CAR-T Approvals by FDA
    • 4.2.6. The First Two CAR-T Approvals by EMA
    • 4.2.7. Approval of Tecartus, Breyanzi and Abecma
    • 4.2.8. NMPA Approval of Relma-cel (Carteyva)
    • 4.2.9. Approval of Carvykti
    • 4.2.10. Approval of NexCAR19 (actalycabtagene autoleucel)
    • 4.2.11. Approval of Yuanruida (inaticabtagene autoleucel)
    • 4.2.12. Approval of Qartemi (varnimcabtagene autoleucel)
    • 4.2.13. Approval of Aucatzyl (obecabtagene autoleucel)
  • 4.3. Current Status of CAR-T Therapy Products
  • 4.4. The Upcoming CAR-T Stars
    • 4.4.1. ALLO-501
    • 4.4.2. CTX-110
    • 4.4.3. UCART19
    • 4.4.4. AUT01
    • 4.4.5. JCARH125
    • 4.4.6. PBCAR20A
    • 4.4.7. UCART123
    • 4.4.8. PRGN-3006
    • 4.4.9. UCART22
    • 4.4.10. UCARTCS1
  • 4.5. Cancer Population Addressed by CAR-T Therapy
  • 4.6. Advantages of CAR-T Cell Therapy
  • 4.7. Disadvantages of CAR-T Cell Therapy

5. SCALABLE MANUFACTURING OF CAR-T CELLS

  • 5.1. The Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • 5.2. The Evolution of CAR-T Cell Manufacturing Platforms
    • 5.2.1. Open vs. Closed Systems
    • 5.2.2. Manual Processing vs. Automation
    • 5.2.3. Autologous vs. Allogeneic CAR-T Manufacturing
    • 5.2.4. Operating Expenses in Autologous CAR-T Manufacturing
    • 5.2.5. Operating Expenses in Allogeneic CAR-T Manufacturing

6. CAR-T TARGET ANTIGENS

  • 6.1. CAR-T Target Antigens in Hematological Cancers
  • 6.2. CAR-T Target Antigens on Solid Tumors
  • 6.3. Common Antigens Targeted by CAR-T Cells in Clinical Trials
    • 6.3.1. Cluster Differentiation 19 (CD19)
    • 6.3.2. Mesothelin
    • 6.3.3. Beta Cell Maturation Agent (BCMA)
    • 6.3.4. GD2
    • 6.3.5. Glypican-3 (GPC3)
    • 6.3.6. Cluster Differentiation-22 (CD22)

7. CAR-T PATENT LANDSCAPE

  • 7.1. Geographical Distribution of CAR-T Patents
  • 7.2. Top Ten Applicants of CAR-T Patents
  • 7.3. Top Ten Inventors of CAR-T Patents
  • 7.4. Top Ten Owners of CAR-T Patents
  • 7.5. Legal Status of CAR-T Patents

8. CAR-T CLINICAL TRIAL LANDSCAPE

  • 8.1. Most Addressed Indications in Clinical Trials
  • 8.2. Current Focus of Ongoing Clinical Trials
  • 8.3. Clinical Trial by Country
  • 8.4. Phase of Studies
  • 8.5. CAR-T Clinical Trials by Funding Type
  • 8.6. Types of Hematological Malignancies Addressed in Clinical Trials
  • 8.7. Simultaneous Targets by one CAR-T
  • 8.8. CAR-T Generation Types used in Clinical Trials
  • 8.9. CAR-T Clinical Trials Focusing on Solid Cancers
  • 8.10. Distribution of CAR-T Trials by Type of SeFv Used
  • 8.11. Distribution of CAR-T Trials by Type of Vectors Used
  • 8.12. Geographical Distribution of CAR-T Studies in Solid Tumors
    • 8.12.1. CAR-T Solid Tumor Clinical Trials by Phase of Study
    • 8.12.2. Funding Types in CAR-T Solid Tumor Clinical Trials
    • 8.12.3. Solid Tumor Types in Clinical Trials
  • 8.13. CAR-T Targeted Biomarkers in Clinical Trials
    • 8.13.1. CAR-T Targeted Indications in the U.S. Clinical Trials
    • 8.13.2. Indications Addressed by CAR-T Clinical Trials in China
    • 8.13.3. Liquid Cancers vs. Solid Cancers in CAR-T Clinical Trials
    • 8.13.4. CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
    • 8.13.5. CAR-T Clinical Trial Sponsor Companies and Institutions in China
    • 8.13.6. CAR-T Trial Sponsor Companies and Institutions in Other Countries
  • 8.14. Improved CAR-T Constructs in Clinical Trials
    • 8.14.1. CAR-T with PD1Fc
    • 8.14.2. CAR-T with Truncated EFGR
    • 8.14.3. CAR-T with IL7 and CCL 19
    • 8.14.4. CAR-T with PD1/CD28 Switch Receptor
    • 8.14.5. CAR-T with PD1 shRNA Expressing Cassette
    • 8.14.6. CAR-T with CTLA-4/PD-1 Antibody
    • 8.14.7. CAR-T with PD-1 Antibodies

9. PUBLISHED CAR-T SCIENTIFIC PAPERS IN PUBMED.GOV

  • 9.1. PubMed.gov Papers on Autologous and Allogeneic CAR-T Therapies
  • 9.2. PubMed.gov Papers on CAR-T for Liquid vs. Solid Cancers, 2013-March 2024
  • 9.3. PubMed Papers on the Five Generation of CARs
  • 9.4. NIH Funding for CAR-T Research

10. CAR-T FUNDING LANDSCAPE

  • 10.1. Venture Capital Funding in CAR-T Sector, 2014to March 2024
    • 10.1.1. Venture Capital Funding for CAR-T Companies by Year, 2014-March 2024
  • 10.2. IPO Funding in Invested in CAR-T Companies, 2014-March 2024
  • 10.3. CAR-T Licensing Deals
  • 10.4. CAR-T Collaboration Deals
  • 10.5. CAR-T Merger and Acquisition (M&A) Deals, 2015-March 2024
  • 10.6. Overview of CAR-T Funding

11. COST OF CAR-T TREATMENT AND REIMBURSEMENT

  • 11.1. New Payment Models
    • 11.1.1. List Price of approved CAR-Ts
    • 11.1.2. Component Cost in addition to Treatment Acquisition Cost
    • 11.1.3. Adverse Event Costs (AEs)
  • 11.2. Reimbursement in the U.S. for CAR-T Therapy
    • 11.2.1. Policy Changes for FY 2024
  • 11.3. Cost of CAR-T Therapies in Europe
    • 11.3.1. Cost Components and Resource Use
    • 11.3.2. Average Total Component Costs for CAR-T Therapy in Former EU-5 and NL
    • 11.3.3. Reimbursement for CAR-T Therapies in Europe
    • 11.3.4. Innovative Reimbursement Schemes in Europe
  • 11.4. Cost & Reimbursement for CAR-T Therapy in Asia
    • 11.4.1. Cost & Reimbursement for CAR-T in Japan
    • 11.4.2. Cost & Reimbursement for CAR-T Therapy in South Korea
    • 11.4.3. Cost & Reimbursement for CAR-T Therapy in Malaysia
    • 11.4.4. Cost & Reimbursement for CAR-T Therapy in Singapore
    • 11.4.5. Cost & Reimbursement for CAR-T Therapy in China
    • 11.4.6. Cost of CAR-T Therapy in India

12. BLOOD CANCERS ADDRESSED BY CAR-T

  • 12.1. Acute Lymphoblastic Leukemia (ALL)
    • 12.1.1. Available Therapies
  • 12.2. Diffuse Large B-Cell Lymphoma (DLBCL)
    • 12.2.1. Available Therapies
  • 12.3. Mantle Cell Lymphoma (MCL)
    • 12.3.1. Available Therapies
  • 12.4. Multiple Myeloma (MM)
    • 12.4.1. Available Therapies
  • 12.5. Follicular Lymphoma
    • 12.5.1. Available Therapies
  • 12.6. The Staggering Cost of Blood Cancer Therapies

13. MARKET ANALYSIS

  • 13.1. Uptake of CAR-T Cell Therapy, 2017-2023
    • 13.1.1. Current Global Market for CAR-T Cell Therapy by Product
  • 13.2. Estimated Global Market for CAR-T Cell Therapy Products, 2024-2032
    • 13.2.1. Global Market for CAR-T Therapy by Geography
    • 13.2.2. Global Market for CAR-T Therapy by Indication
  • 13.3. Challenges & Opportunities for CAR-T Therapies in Blood Cancers
    • 13.3.1. Barriers to Access
    • 13.3.2. Targets other than CD19
    • 13.3.3. Resistance for CAR-T Therapy
    • 13.3.4. Manufacturing Time
    • 13.3.5. Autologous vs. Allogeneic CAR-Ts

14. CAR-T COMPNIES: AN OVERVIEW

  • 14.1 2seventy bio
    • 14.1.1. Abecma (idecabtagene vicleucel)
  • 14.2. Abintus Bio, Inc.
  • 14.3. AffyImmune Therapeutics, Inc.
    • 14.3.1. Affinity-Tuned CARs
      • 14.3.1.1. ICAM-1: AffyImmune's Target Antigen
      • 14.3.1.2. Targeted Indication
  • 14.4. Aleta BioTherapeutics
    • 14.4.1. Aleta's CAR-T Engager Pipeline
  • 14.5. Allogene Therapeutics
    • 14.5.1. AlloCAR-T
      • 14.5.1.1. Manufacturing of AlloCAR-T
  • 14.6. Anixa Biosciences, Inc.
  • 14.7. Arbele, Ltd.
    • 14.7.1. Advanced Cell Therapy
  • 14.8. Arcellx
    • 14.8.1. D-Domain Technology
    • 14.8.2. ddCAR Platform
    • 14.8.3. ARC-SparX Platform
  • 14.9. Atara Biotherapeutics
    • 14.9.1. Technology
    • 14.9.2. Allogeneic CAR-T Programs
  • 14.10. Aurora BioPharma
    • 14.10.1. HER2 Platform
  • 14.11. Autolus Therapeutics plc
    • 14.11.1. Technology
    • 14.11.2. CAR-T Cell Production
    • 14.11.3. Manufacturing
    • 14.11.4. Therapies in Development
      • 14.11.4.1. obe-cel
  • 14.12. AvenCell Europe GmbH
    • 14.12.1. Universal Switchable CAR
    • 14.12.2. Allogeneic Platform
    • 14.12.3. Clinical & Preclinical Pipeline Overview
  • 14.13. Beam Therapeutics, Inc.
    • 14.13.1. BEAM-201
  • 14.14. Bellicum Pharmaceuticals
    • 14.14.1. GoCAR Technology
    • 14.14.2. CaspaCIDe Safety Switch
  • 14.15. BioNTech
    • 14.15.1. BioNTech's Engineered Cell Therapies
    • 14.15.2. BN211
    • 14.15.3. BN212
  • 14.16. Biosceptre
    • 14.16.1. Biosceptre's Unique Target nf2X7
    • 14.16.2. BRiDGECAR Program
  • 14.17. Bluebird bio
    • 14.17.1. Blebird bio's CAR-T Collaborations
    • 14.17.2. Collaboration with BMS
    • 14.17.3. Collaboration with TC BioPharm
    • 14.17.4. Collaboration with Inhibrx
    • 14.17.5. Collaboration with PsiOxus
  • 14.18. Bristol Myers Squibb/Celgene Corporation
    • 14.18.1. Products
      • 14.18.1.1. Abecma (idecabtagene vicleucel)
      • 14.18.1.2. Breyanzi (lisocabtagene maraleucel)
  • 14.19. Cabaletta Bio
    • 14.19.1. CABA Platform
    • 14.19.2. Cabaletta's Pipeline
  • 14.20. Carina Biotech
  • 14.21. CARsgen Therapeutics
    • 14.21.1. CycloCAR-T
    • 14.21.2. THANK-uCAR
    • 14.21.3. LADAR
  • 14.22. Cartesian Therapeutics
    • 14.22.1. mRNA CAR-T Cell Program (RNA Armory)
    • 14.22.2. Pipeline
  • 14.23. CARTherics Pty Ltd.
    • 14.23.1. Autologous CAR-T Cells
  • 14.24. CASI Pharmaceuticals
    • 14.24.1. Yuanruida (inaticabtagene autoleucel; CNCT19)
  • 14.25. Cellectis
    • 14.25.1. TAL nucleases, or TALEN
    • 14.25.2. Gene Editing
    • 14.25.3. PulseAgile Technology
    • 14.25.4. Main Product Candidates
  • 14.26. Celularity, Inc.
    • 14.26.1. P CAR-T
  • 14.27. Celyad Oncology
    • 14.27.1. NKG2D-Based CAR-T Cells
    • 14.27.2. Multispecific CAR
    • 14.27.3. Short Hairpin RNA-based Platform
    • 14.27.4. CAR-T Therapy Development Services
    • 14.27.5. Biomarker Identification and Selection
    • 14.27.6. scFv Generation
    • 14.27.7. CAR-T Gene Packaging and Delivery
    • 14.27.8. Virus Testing Service
    • 14.27.9. CAR Cell in vitro Assay Service
    • 14.27.10. CAR-T Preclinical in vivo Assay
    • 14.27.11. IND Development for CAR-T Cell Therapy
    • 14.27.12. GMP Production for CAR-T Products
    • 14.27.13. CAR-T Clinical Trial Services
  • 14.28. CRISPR Therapeutics
    • 14.28.1. CRISPR Therapeutics' Immuno-Oncology Programs
    • 14.28.2. CRISPR/Cas9-enabled Allogeneic CAR-T Design
  • 14.29. Curocell, Inc.
    • 14.29.1. OVIS Technology
  • 14.30. DiaCarta
    • 14.30.1. Personalized CAR-T Immunotherapy Platform
  • 14.31. Elicera Therapeutics AB
    • 14.31.1. iTANK CAR-T Technology
    • 14.31.2. Elicera's Product Pipeline
  • 14.32. EXUMA Biotech
    • 14.32.1. TMR CAR-T Technology
    • 14.32.2. CCT3 CAR-T
    • 14.32.3. rPOC SC CAR-TaNKs
    • 14.32.4. GCAR "in vivo Cell Therapy"
  • 14.33. Fate Therapeutics
    • 14.33.1. FT819
    • 14.33.2. FT825
  • 14.34. Galapagos NV
  • 14.35. Gilead Sciences, Inc.
    • 14.35.1. CAR-T Products
      • 14.35.1.1. Tecartus (brexucabtagene autoleucel)
      • 14.34.1.2. Yescarta (axicabtagene ciloleucel)
  • 14.36. Gracell Biotechnologies
    • 14.36.1. FasTCAR
    • 14.36.2. TruUCAR
    • 14.36.3. SMART CAR-T
    • 14.36.4. Gracell's Product Pipeline
  • 14.37. IASO Biotherapeutics
    • 14.37.1. Technology Platforms
    • 14.37.2. Fully Human Antibody Discovery Platform
    • 14.37.3. High-Throughput Screening Platform for CAR-T Candidates
    • 14.37.4. Universal CAR-T Technology Platform
    • 14.37.5. CAR-T Manufacturing Technology Platform
    • 14.37.6. IASO's Diverse Product Pipeline
  • 14.38. ImmPACT Bio
    • 14.38.1. CD19/20 Bispecific CAR
    • 14.38.2. TGF-Beta
  • 14.39. Immuneel Therapeutics, Pvt., Ltd.
    • 14.39.1. Immuneel's R&D Roadmap
  • 14.40. ImmunoACT
    • 14.40.1. NexCAR19 (Actalycabtagene autoleucel)
  • 14.41. Interius BioTherapeutics
    • 14.41.1. Core Technology
  • 14.42. Juventas Cell Therapy
    • 14.42.1. Yuanruida (inaticabtagene autoleucel)
  • 14.43. JW Therapeutics
    • 14.43.1. Carteyva (relmacabtagene autoleucel; relma-cel)
  • 14.44. Kite Pharma (Gilead)
    • 14.44.1. Kite's Marketed CAR-T Products
      • 14.44.1.1. Yescarta (axicabtagene ciloleucel)
      • 14.44.1.2. Tecartus (brexucabtagene autoleucel)
    • 14.44.2. Kite's Pipeline Cancer Therapies
  • 14.45. Kyverna Therapeutics
    • 14.45.1. Kyverna's CAR-T Therapy for Autoimmune Diseases
  • 14.46. Legend Biotech
    • 14.46.1. Technology Platforms
      • 14.46.1.1. CAR-T
      • 14.46.1.2. CAR-Gamma-Delta- T
      • 14.46.1.3. CAR-NK
      • 14.46.1.4. Non-Gene-Editing Universal CAR-T
    • 14.46.2. Product Pipeline
  • 14.47. Leucid Bio
    • 14.47.1. Leucid's Lateral CAR-Platform
    • 14.47.2. LEU011 - NKG2D CAR-T Cell Therapy
    • 14.47.3. T2, Gamma-Delta- T-Cells for Off-The-Shelf Therapy
    • 14.47.4. T4 Immunotherapy
    • 14.47.5. Novel Manufacturing Platform
  • 14.48. Luminary Therapeutics, Inc.
    • 14.48.1. Allogeneic Gamma 2.0+ Platform
    • 14.48.2. Non-Viral Gene Modification Process
    • 14.48.3. Split Co-Stim Dual CAR
    • 14.48.4. Ligand-Based CAR to Target Three Antigens
    • 14.48.5. Product Pipeline
  • 14.49. Lyell Immunopharma, Inc.
    • 14.49.1. Technology
      • 14.49.1.1. Gen-R Technology
      • 14.49.1.2. Epi-R Technology
    • 14.49.2. Lyell's Product Pipeline
  • 14.50. March Biosciences
    • 14.50.1. MB-105
    • 14.50.2. March Biosciences' Pipeline
  • 14.51. MaxCyte, Inc.
    • 14.51.1. Technology: Flow Electroporation
    • 14.51.2. MaxCyte's Electroporation Systems
      • 14.51.2.1. ATx
      • 14.51.2.2. GTx
      • 14.51.2.3. STx
      • 14.51.2.4. VLx
  • 14.52. Minerva Biotechnologies Corporation
    • 14.52.1. CAR-T (huMNC2-CAR44)
  • 14.53. Mustang Bio
    • 14.53.1. Mustang's CAR-T Focus
  • 14.54. Noile-Immune Biotech
    • 14.54.1. PRIME CAR-T
  • 14.55. Novartis AG
    • 14.55.1. The Pioneer in CAR-T
    • 14.55.2. Kymriah (tisagenlecleucel)
    • 14.55.3. T-Charge Platform
      • 14.55.3.1. Phase I YTB323 Clinical Study
      • 14.55.3.2. Phase I PHE 885 Clinical Study
  • 14.56. Oncternal Therapeutics
    • 14.56.1. ONCT-808
  • 14.57. Oxford Biomedica plc
    • 14.57.1. LentiVector Platform
    • 14.57.2. inAAVate Platform
    • 14.57.3. CDMO Services
  • 14.58. PeproMene Bio, Inc.
    • 14.58.1. BAFFR CAR-T Cells
  • 14.59. Poseida Therapeutics, Inc.
    • 14.59.1. Poseida's Genetic Engineering Platforms
    • 14.59.2. PiggyBac Platform for Insertion
    • 14.59.3. Cas-CLOVER Platform for Editing
    • 14.59.4. Poseida's CAR-T Product Candidates
  • 14.60. Precigen, Inc.
    • 14.60.1. UltraCAR-T
    • 14.60.2. Sleeping Beauty System
    • 14.60.3. UltraPorator System
    • 14.60.4. Product Pipeline
  • 14.61. Prescient Therapeutics
    • 14.61.1. OmniCAR
    • 14.61.2. CellPryme
  • 14.62. ProMab Biotechnologies, Inc.
    • 14.62.1. ProMab's CAR-T Cells
    • 14.62.2. ProMab's Services
    • 14.62.3. ProMab's Preclinical and Clinical Study Services
  • 14.63. SOTIO Biotech BV
    • 14.63.1. BOXR Technology
    • 14.63.2. BOXR1030
  • 14.64. Syngene International, Ltd.
    • 14.64.1. CAR-T Services
  • 14.65. Synthekine
    • 14.65.1. STK-009 + SYNCAR-001
  • 14.66. TC BioPharm
    • 14.66.1. Gamma Delta T Cells
    • 14.66.2. Cell Banks
    • 14.66.3. Co-Stim CAR-T
    • 14.66.4. Product Pipeline
      • 14.66.4.1. OmnImmune
    • 14.66.5. CAR-T Programs
  • 14.67. T-CURX
    • 14.67.1. Technologies
  • 14.68. Umoja Biopharma
    • 14.68.1. Umoja's Technology Platforms
      • 14.68.1.1. VivoVec in vivo Gene Delivery
      • 14.68.1.2. RACR-Induced Cytotoxic Lymphocytes (iCIL)
      • 14.68.1.3. RACR/CAR: in vivo Cell Programming
      • 14.68.1.4. TumorTag: Universal CAR Tumor Targeting
  • 14.69. ViTToria Biotherapeutics
    • 14.69.1. Senza5
    • 14.69.2. VIPER-101
  • 14.70. Vor Biopharma
    • 14.70.1. Vor Biopharma's Approach
  • 14.71. Wugen
  • 14.72. WuXi Advanced Therapies
    • 14.72.1. WuXi's Closed Process CAR-T manufacturing
  • 14.73. Xenetic Biosciences
    • 14.73.1. DNase-based Oncology Platform
  • 14.74. Xyphos Biosciences, Inc.
    • 14.74.1. ACCEL & UDC Technology
    • 14.74.2. convertibleCAR
    • 14.74.3. Universal Donor Cells

INDEX OF FIGURES

  • FIGURE 2.1: The Basic Structure of a T cell
  • FIGURE 2.2: Binding of a T cell on to an Infected Cell
  • FIGURE 2.3: Components of a CAR-T cell
  • FIGURE 2.4: The Three Domains of a CAR
  • FIGURE 2.5: The first Generation CARs
  • FIGURE 2.6: Second Generation CARs
  • FIGURE 2.7: Third Generation CARs
  • FIGURE 2.8: Fourth Generation CARs
  • FIGURE 2.9: Fifth Generation CARs
  • FIGURE 2.10: CAR Constructs in the FDA Approved CAR-T Cell Products
  • FIGURE 2.11: Antigens Present on Normal and Cancer Cells
  • FIGURE 2.12: Preparation and Administration of CAR-T cell Therapy
  • FIGURE 2.13: Kymriah in Infusion Bag
  • FIGURE 2.14: Yescarta in Infusion Bag
  • FIGURE 2.15: Tecartus in Infusion Bag
  • FIGURE 2.16: Carvykti in Infusion Bag
  • FIGURE 2.17: Abecma in the Infusion Bag
  • FIGURE 2.18: Breyanzi in Package
  • FIGURE 2.19: Relma-cel Infusion Bag
  • FIGURE 3.1: Switchable CARs [sCARs; Universal CARs]
  • FIGURE 3.2: Action of Suicide Genes
  • FIGURE 3.3: Graphical Abstract for Transient Transfection
  • FIGURE 3.4: A Model of Armored CAR
  • FIGURE 4.1: The Five Generations of CARs
  • FIGURE 5.1: Manufacturing Process of Clinical-Scale Autologous CAR-T Therapies
  • FIGURE 5.2: G-Rex Bioreactors
  • FIGURE 5.3: CliniMACS Prodigy
  • FIGURE 5.4: Scaling Up of Allogeneic CAR-T Cells
  • FIGURE 5.5: Operating Expenses for Autologous CAR-T Manufacturing
  • FIGURE 5.6: Operating Expenses in Allogeneic CAR-T Manufacturing
  • FIGURE 6.1: CAR-T Target Antigens Evaluated in Clinical Trials
  • FIGURE 8.1: CAR-T Clinical Trials by Phase of Study, March 2024
  • FIGURE 8.2: Types of Hematological Malignancies Addressed in Clinical Trials
  • FIGURE 8.3: Studies for Simultaneous Targets by One CAR-T
  • FIGURE 8.4: CAR-T Generation Types used in Clinical Trials
  • FIGURE 8.5: Distribution of CAR-T Trials by Type of SeFv Used
  • FIGURE 8.6: Distribution of CAR-T Trials by Type of Vectors Used
  • FIGURE 8.7: Solid Tumor Types in Clinical Trials, March 2024
  • FIGURE 8.8: Liquid Cancers vs. Solid Cancers in CAR-T Clinical Trials
  • FIGURE 9.1: Number of Published CAR-T Papers on PubMed.gov, 2000-March 2024
  • FIGURE 9.2: PubMed Papers on Autologous vs. Allogeneic CAR-T Therapies, 2000-2024
  • FIGURE 9.3: PubMed Papers on CAR-T for Liquid vs. Solid Cancers, 2013-March 2024
  • FIGURE 9.4: PubMed Papers on the Five Generation of CARs
  • FIGURE 10.1: Venture Capital Funding for CAR-T Companies by Year, 2014-March 2024
  • FIGURE 10.2: IPO Invested in CAR-T Companies, 2014-March 2024
  • FIGURE 13.1: Uptake of U.S.FDA-Approved CAR-Ts, 2017-2023
  • FIGURE 13.2: Revenue Generation by CAR-T Therapy by Product, 2017-2023
  • FIGURE 13.3: Estimated Modest Growth of CAR-T Market by Product, 2023-2032
  • FIGURE 13.4: Global Market for CAR-T Products by Geography, 2023-2032
  • FIGURE 13.5: Global Market for CAR-T Therapies by Indication, 2024-2032
  • FIGURE 14.1: Atara's Approach to Allogeneic Cell Therapy
  • FIGURE 14.2: Illustration of CycloCAR-T
  • FIGURE 14.3: Illustration of THANK-uCAR-T
  • FIGURE 14.5: Schematic of Allogeneic P CAR-T with TCR KO
  • FIGURE 14.6: NKG2D-based CAR
  • FIGURE 14.7: Celyad's Multispecific CAR
  • FIGURE 14.8: CRISPR/Cas9-enabled Allogeneic CAR-T Design
  • FIGURE 14.9: FT819
  • FIGURE 14.10: FT825
  • FIGURE 14.11: FasTCAR vs. Conventional CAR-T Manufacturing Time
  • FIGURE 14.12: Action of TruUCAR
  • FIGURE 14.13: SMART CAR-T
  • FIGURE 14.14: CD19/CD20 CAR-T Technology
  • FIGURE 14.15: TGF-Beta- Bispecific CAR Technology
  • FIGURE 14.16: Lateral CAR
  • FIGURE 14.17: T4 T-Cell
  • FIGURE 14.18: Split Co-Stim Dual CAR
  • FIGURE 14.19: Ligand-Based CAR to Target Three Antigens
  • FIGURE 14.20: Natural Killing of CAR-T Cells
  • FIGURE 14.21: ATx
  • FIGURE 14.22: GTx
  • FIGURE 14.23: STx
  • FIGURE 14.24: VLx
  • FIGURE 14.25: Features of PRIME CAR-T Cell Therapy
  • FIGURE 14.26: BAFFR CAR-T Cells
  • FIGURE 14.27: Poseida's PiggyBac Platform for Insertion
  • FIGURE 14.28: Poseida's Cas-CLOVER Platform for Editing
  • FIGURE 14.29: UltraCAR-T Cell
  • FIGURE 14.30: Precigen's Ultraporator System
  • FIGURE 14.31: Prescient's OmniCAR
  • FIGURE 14.32: VIPER-101, the Lead Program of ViTToria
  • FIGURE 14.33: WuXi's Closed Process CAR-T Platform
  • FIGURE 14.34: Convertible CAR Parts
  • FIGURE 14.35: Xyphos' Universal Donor Cells

INDEX OF TABLES

  • TABLE 2.1: Potential CAR-T Targeted Antigens Present on Hematological Malignant Cells
  • TABLE 2.2: Key Differences between the Available Vectors
  • TABLE 2.3: The 11 CAR-T Cell Therapies Available in the Global Market
  • TABLE 2.4: Common Toxicities Associated with CAR-T Treatment
  • TABLE 3.1: Strategies for Future CAR-T Therapies
  • TABLE 3.2: A Sample of CAR-T Studies on Solid Tumors
  • TABLE 3.3: New Target Antigens and New Target Cancers
  • TABLE 3.4: A sample of Allogeneic CAR-T Studies
  • TABLE 4.1: History of Development of CAR-T Cell Therapy
  • TABLE 4.2: Approved CAR-T Products, their Developers and Indications
  • TABLE 4.3: Upcoming CAR-T Stars
  • TABLE 4.4: Cancer Population Addresses by CAR-T Therapy
  • TABLE 6.1: CAR-T Target Antigens in Hematological Cancers
  • TABLE 6.2: Targeted Antigens involved in the Approved CAR-Ts
  • TABLE 7.1: Geographical Distribution of CAR-T Patents, March 2024
  • TABLE 7.2: Top Ten Applicants for CAR-T Patents, March 2024
  • TABLE 7.3: Top Ten Inventors of CAR-T Patents, March 2024
  • TABLE 7.4: Top Ten Owners of CAR-T Patents, March 2024
  • TABLE 7.5: Legal Status of CAR-T Patent Applications, March 2024
  • TABLE 8.1: CAR-T Clinical Trials by Country, March 2024
  • TABLE 8.2: Number of CAR-T Clinical Trials by Funding Type, March 2024
  • TABLE 8.3: Clinical Trials Focusing on Solid Tumors by Country, March 2024
  • TABLE 8.4: CAR-T Solid Tumor Clinical Trials by Phase of Study, March 2024
  • TABLE 8.5: Funding Types in CAR-T Solid Tumor Clinical Trials, March 2024
  • TABLE 8.6: Percent Biomarker Distribution in CAR-T Clinical Trials
  • TABLE 8.7: CAR-T Targeted Indications in the U.S. Clinical Trials
  • TABLE 8.8: Indications Addressed by CAR-T Clinical Trials in China
  • TABLE 8.9: CAR-T Clinical Trial Sponsor Companies and Institutions in the U.S.
  • TABLE 8.10: CAR-T Clinical Trial Sponsor Companies and Institutions in China
  • TABLE 8.11: CAR-T Clinical Trial Sponsor Companies and Institutions in Other Countries
  • TABLE 8.12: Clinical Trials of 4th, 5th gen. and Gene Edited CAR-Ts
  • TABLE 9.1: NIH Funding for CAR-T Research, 2024
  • TABLE 10.1: CAR-T Venture Capital Funding, 2014-March 2024
  • TABLE 10.2: IPO Invested in CAR-T Companies, 2014-March 2024
  • TABLE 10.3: CAR-T Licensing Deals, 2015-March 2024
  • TABLE 10.4: CAR-T Collaboration Deals Signed between 2013 and March 2024
  • TABLE 10.5: CAR-T Merger and Acquisition (M&A) Deals, 2015-March 2024
  • TABLE 10.6: Overview of CAR-T Funding, 2014-March 2024
  • TABLE 11.1: List Prices of CAR-T Cells
  • TABLE 11.2: Pre-, Peri-, and Post Infusion Unit Costs
  • TABLE 11.3: Adverse Events Rates and Unit Costs of Management
  • TABLE 11.4: Reimbursement for CAR-T Cases, FY 2023 vs. FY 2024
  • TABLE 11.5: Cost of CAR-T cell Products in the EU Countries
  • TABLE 11.6: Cost Components and Resource Use of Pre- and Post- CAR-T Cell Therapy
  • TABLE 11.7: Average Total Costs Pre- and Post- CAR-T Treatment in Former EU 5 and NL
  • TABLE 11.8: CAR-T Reimbursement Schemes in Europe
  • TABLE 12.1: FDA-Approved Therapies for R/R ALL Pediatric and Young Adult Patients
  • TABLE 12.2: FDA Approved Therapies for DLBCL
  • TABLE 12.3: FDA Approved Therapies for MCL
  • TABLE 12.4: FDA Approved Drugs for Multiple Myeloma
  • TABLE 12.5: FDA-Approved Drugs for Follicular Lymphoma
  • TABLE 12.6: Cost of Treating Blood Cancers
  • TABLE 13.1: Uptake of U.S. FDA-Approved CAR-Ts, 2017-2023
  • TABLE 13.2: Revenue Generation by CAR-T Therapy by Product, 2017-2023
  • TABLE 13.3: Estimated Modest Growth of CAR-T Cell Market by Product, 2023-2032
  • TABLE 13.4: Global Market for CAR-T Products by Geography, 2023-2032
  • TABLE 13.5: Global Market for CAR-T Therapies by Indication, 2024-2032
  • TABLE 14.1: AffyImmune's Affinity-Tuned Pipeline Products
  • TABLE 14.2: Aleta's CAR-T Engager Pipeline
  • TABLE 14.3: Allogene's AlloCAR-T Pipeline
  • TABLE 14.4: Anixa's CAR-T Pipeline
  • TABLE 14.5: Arbele's Advanced Cell Therapy Product Candidates
  • TABLE 14.6: ArcellX's Current Product Pipeline
  • TABLE 14.7: Atara's Product Pipeline
  • TABLE 14.8: Autolus' Therapies in Development
  • TABLE 14.9: Clinical & Preclinical Pipeline Overview
  • TABLE 14.10: Bellicum's Pipeline
  • TABLE 14.11: BRiDGECAR Program
  • TABLE 14.12: Cabaletta's Autoimmune Therapy Candidates in Development
  • TABLE 14.13: Carina's Clinical Programs
  • TABLE 14.14: CARsgen's Product Pipeline
  • TABLE 14.15: Cartesian's Product Pipeline
  • TABLE 14.16: Cellectis' Allogeneic CAR-T Cell Product Pipeline
  • TABLE 14.17: CRISPR Therapeutics' CAR-T Programs
  • TABLE 14.18: Elicera's Product Pipeline
  • TABLE 14.19: EXUMA's Pipeline Assets
  • TABLE 14.20: Galapagos' Oncology CAR-T Pipeline
  • TABLE 14.21: Gracell's Rich Product Pipeline
  • TABLE 14.22: IASO's Diverse Product Pipeline
  • TABLE 14.23: ImmPACT Bio's Product Pipeline
  • TABLE 14.24: Immuneels Product Pipeline
  • TABLE 14.25: JW Therapeutics' Product Pipeline
  • TABLE 14.26: Kite's Pipeline Cancer Therapies
  • TABLE 14.27: Product Pipeline to address Autoimmune Diseases
  • TABLE 14.28: Legend Biotech's Product Pipeline
  • TABLE 14.29: Leucid's Product Pipeline
  • TABLE 14.30: Luminary's Product Pipeline
  • TABLE 14.31: Lyell's Product Pipeline
  • TABLE 14.32: March Biosciences' Product Pipeline
  • TABLE 14.33: A Comparison Guide for MaxCyte's Electroporation Systems
  • TABLE 14.34: Minerva's CAR-T Pipeline Products for Solid Tumors
  • TABLE 14.35: Mustang's CAR-T Product Candidates
  • TABLE 14.36: Noile-Immune's PRIME-Based Product Pipeline
  • TABLE 14.37: Oxford Biomedica's CDMO Services
  • TABLE 14.38: PeproMene's Product Pipeline
  • TABLE 14.39: Poseida's CAR-T Product Pipeline
  • TABLE 14.40: Precigen's UltraCAR-T Pipeline
  • TABLE 14.41: Prescient's CAR-T Pruct Pipeline
  • TABLE 14.42: ProMabs CAR-T Cells
  • TABLE 14.43: ProMab's Discovery Services Plans & Prices
  • TABLE 14.44: Synthekine's Pipeline with SYNCAR-001 + STK-009
  • TABLE 14.45: T-CURX' Product Candidates in Clinical Trials
  • TABLE 14.46: Umoja's Product Pipeline
  • TABLE 14.47: Vor Biopharma's Current Product Pipeline
  • TABLE 14.48: Wugen's Product Pipeline
  • TABLE 14.49: Xenetic's CAR-T Product Pipeline